SCHEMBL8265268

SCHEMBL8265268

O=Cc1cn(CCCC(=O)O)c2ccccc12

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.65
HTT P42858 3/20 0.65
SMN1; SMN2 Q16637 3/20 0.65
NPC1 O15118 2/20 0.65
MAPT P10636 2/20 0.65
RAB9A P51151 2/20 0.65
LMNA P02545 1/20 0.65
HPGD P15428 1/20 0.65
PTGDR2 Q9Y5Y4 1/20 0.58
FABP4 P15090 2/20 0.55
FABP5 Q01469 2/20 0.55
POLB P06746 2/20 0.52
CREBBP Q92793 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
IMPDH2 P12268 1/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1249875 0.91 CREBBP (0.61) ALDH1A1HTTSMN1; SMN2NPC1MAPT
SCHEMBL8264387 0.89 ALDH1A1 (0.61) ALDH1A1HTTSMN1; SMN2NPC1MAPT
SCHEMBL14519061 0.85 ALDH1A1 (0.71) ALDH1A1HTTSMN1; SMN2NPC1MAPT
SCHEMBL1536915 0.84 ALDH1A1 (0.60) ALDH1A1HTTSMN1; SMN2NPC1MAPT
SCHEMBL8264365 0.84 ALDH1A1 (0.61) ALDH1A1HTTSMN1; SMN2NPC1MAPT
SCHEMBL16223080 0.84 ALDH1A1 (0.66) ALDH1A1HTTSMN1; SMN2NPC1MAPT
SCHEMBL28479263 0.82 ALDH1A1 (0.64) ALDH1A1HTTSMN1; SMN2NPC1MAPT
SCHEMBL1536930 0.82 ALDH1A1 (0.61) ALDH1A1HTTSMN1; SMN2NPC1MAPT
SCHEMBL29952467 0.82 ALDH1A1 (0.66) ALDH1A1HTTSMN1; SMN2NPC1MAPT
SCHEMBL1250173 0.82 ALDH1A1 (0.66) ALDH1A1HTTSMN1; SMN2NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178559-B2 Organic compounds NOVARTIS AG (CH) 2012-05-15 US disclosed
US-8178559-B2 Organic compounds NOVARTIS AG (CH) 2012-05-15 US disclosed
US-8084450-B2 Organic compounds NOVARTIS AG (CH) 2011-12-27 US disclosed
US-8084450-B2 Organic compounds NOVARTIS AG (CH) 2011-12-27 US disclosed
US-20110263560-A1 Organic Compounds NOVARTIS AG (CH) 2011-10-27 US disclosed
US-20110263560-A1 Organic Compounds NOVARTIS AG (CH) 2011-10-27 US disclosed
EP-2177518-A1 Organic compounds Novartis AG (CH) 2010-04-21 EP disclosed
US-20090312304-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-12-17 US disclosed
US-20090312304-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-12-17 US disclosed
EP-1833816-B1 SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS NOVARTIS AG (CH) 2009-11-11 EP disclosed
WO-2006069788-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263560-A1 Organic Compounds REN, ACE, OTC ALDH1A1 21/4885HTT 1273/4885SMN1; SMN2 2243/4885
US-20090312304-A1 ORGANIC COMPOUNDS REN, ACE, PIGO ALDH1A1 36/4885HTT 1746/4885SMN1; SMN2 2488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.